BidaskClub lowered shares of ICU Medical, Inc. (NASDAQ:ICUI) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.
Several other brokerages have also weighed in on ICUI. Zacks Investment Research raised ICU Medical from a hold rating to a buy rating and set a $193.00 target price on the stock in a research report on Thursday, July 20th. Roth Capital lowered ICU Medical from a buy rating to a neutral rating in a research report on Thursday, May 11th. They noted that the move was a valuation call. Finally, Sidoti lowered ICU Medical from a buy rating to a neutral rating in a research report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. ICU Medical presently has an average rating of Hold and a consensus target price of $193.00.
Shares of ICU Medical (NASDAQ ICUI) traded down 1.05% during mid-day trading on Wednesday, hitting $164.90. The stock had a trading volume of 157,095 shares. The company has a 50-day moving average of $172.11 and a 200 day moving average of $158.73. ICU Medical has a one year low of $120.14 and a one year high of $176.50. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of 64.92 and a beta of 0.37.
ICU Medical (NASDAQ:ICUI) last issued its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing the consensus estimate of $0.58 by $0.06. ICU Medical had a return on equity of 7.56% and a net margin of 6.10%. The firm had revenue of $331.51 million during the quarter, compared to analyst estimates of $318.30 million. During the same period in the previous year, the company earned $1.15 earnings per share. The business’s revenue for the quarter was up 242.8% on a year-over-year basis. On average, equities research analysts forecast that ICU Medical will post $4.14 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/13/icu-medical-inc-icui-downgraded-by-bidaskclub-to-sell.html.
In other ICU Medical news, VP Alison D. Burcar sold 18,290 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $160.72, for a total value of $2,939,568.80. Following the transaction, the vice president now directly owns 3,727 shares of the company’s stock, valued at approximately $599,003.44. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Vivek Jain sold 69,014 shares of the company’s stock in a transaction dated Friday, July 7th. The stock was sold at an average price of $171.10, for a total value of $11,808,295.40. Following the completion of the transaction, the chief executive officer now directly owns 110,925 shares in the company, valued at $18,979,267.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 227,349 shares of company stock worth $38,623,370. Insiders own 15.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning raised its position in shares of ICU Medical by 315.6% in the first quarter. Creative Planning now owns 665 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 505 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ICU Medical by 10.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 707 shares of the medical instruments supplier’s stock worth $122,000 after buying an additional 66 shares in the last quarter. Riverhead Capital Management LLC raised its position in shares of ICU Medical by 99.8% in the second quarter. Riverhead Capital Management LLC now owns 999 shares of the medical instruments supplier’s stock worth $172,000 after buying an additional 499 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of ICU Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 1,050 shares of the medical instruments supplier’s stock worth $181,000 after buying an additional 157 shares in the last quarter. Finally, Parametrica Management Ltd bought a new position in shares of ICU Medical during the second quarter worth approximately $213,000. 77.85% of the stock is currently owned by institutional investors and hedge funds.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
What are top analysts saying about ICU Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ICU Medical Inc. and related companies.